FunPep Company Limited (JP:4881)
:4881
Want to see JP:4881 full AI Analyst Report?
Top Page
FunPep Company Limited
(4881)
Select Model
Select Model
Rating:41Neutral
Price Target:
¥58.00
▼(-26.58% Downside)
Action:Reiterated
Date:05/22/26
The score is weighed down primarily by very weak financial performance—sharp revenue collapse, widening losses, and accelerating cash burn—despite the benefit of having zero debt. Technicals further pressure the score as the stock is in a clear downtrend with bearish momentum (though oversold). Valuation contributes limited support given the negative P/E and no dividend yield data.
Positive Factors
Clean Balance Sheet
Having zero debt is a durable structural strength for an early-stage biotech: it lowers refinancing and interest-rate risk, preserves strategic optionality for R&D spend or partnerships, and gives management flexibility to raise capital on better terms when needed without immediate leverage constraints.
Negative Factors
Revenue Collapse & Losses
A near-total revenue collapse alongside widening net losses signals impaired commercial traction or lapses in partner income, undermining sustainable growth. Persistently negative earnings reduce reinvestment capacity, raise reliance on external funding, and erode investor confidence in long-term viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Clean Balance Sheet
Having zero debt is a durable structural strength for an early-stage biotech: it lowers refinancing and interest-rate risk, preserves strategic optionality for R&D spend or partnerships, and gives management flexibility to raise capital on better terms when needed without immediate leverage constraints.
Read all positive factors
FunPep Company Limited (4881) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥3.04B
Dividend YieldN/A
Average Volume (3M)245.82K
Price to Earnings (P/E)―
Beta (1Y)1.04
Revenue Growth-94.55%
EPS Growth7.93%
CountryJP
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-41.98
Shares Outstanding50,666,700
10 Day Avg. Volume262,310
30 Day Avg. Volume245,823
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.13
Price to Sales (P/S)9943.96
P/FCF Ratio-2.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-19.9
Revenue Forecast (FY)¥300.00M
FunPep Company Limited Business Overview & Revenue Model
Company Description
FunPep Company Limited specializes in the discovery and advancement of pharmaceutical drugs, functional cosmetics, and medical devices, leveraging its core technology in functional peptides. The company's development pipeline prominently features ...
How the Company Makes Money
FunPep Company Limited generates revenue through its drug development pipeline, primarily by licensing its proprietary peptide technologies to pharmaceutical companies and forming strategic partnerships for clinical trials and commercialization. T...
FunPep Company Limited Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
58
Neutral
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.65M | 314.00K | 6.13M | 530.00K | 1.07M | 126.87M |
| Gross Profit | -38.13M | -41.58M | -37.86M | -43.03M | -12.84M | 125.12M |
| EBITDA | -1.36B | -1.61B | -859.23M | -950.54M | -1.16B | -743.67M |
| Net Income | -1.40B | -1.91B | -889.09M | -933.42M | -1.17B | -682.26M |
Balance Sheet | ||||||
| Total Assets | 3.01B | 1.98B | 3.11B | 2.49B | 2.99B | 3.36B |
| Cash, Cash Equivalents and Short-Term Investments | 2.33B | 1.77B | 2.35B | 1.79B | 2.25B | 3.01B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 538.78M | 516.73M | 566.27M | 192.61M | 298.11M | 188.67M |
| Stockholders Equity | 2.47B | 1.46B | 2.55B | 2.30B | 2.69B | 3.18B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -1.39B | -537.60M | -989.87M | -1.07B | -892.79M |
| Operating Cash Flow | 0.00 | -1.39B | -536.74M | -988.82M | -1.05B | -887.47M |
| Investing Cash Flow | 0.00 | -993.00K | -30.83M | -1.05M | -19.14M | -4.75M |
| Financing Cash Flow | 0.00 | 810.93M | 1.12B | 537.81M | 245.13M | 282.68M |
FunPep Company Limited Technical Analysis
Negative
79.00
Price Trends
69.10
Negative
81.67
Negative
89.56
Negative
Market Momentum
-2.67
Negative
41.64
Neutral
21.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4881, the sentiment is Negative. The current price of 79 is above the 20-day moving average (MA) of 60.20, above the 50-day MA of 69.10, and below the 200-day MA of 89.56, indicating a bearish trend. The MACD of -2.67 indicates Negative momentum. The RSI at 41.64 is Neutral, neither overbought nor oversold. The STOCH value of 21.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4881.
FunPep Company Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | ¥8.54B | 25.96 | ― | ― | 3.66% | 32.11% | |
52 Neutral | ¥5.03B | 20.06 | ― | 1.62% | -5.13% | -68.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ¥4.72B | -1.42 | ― | 5.44% | -16.97% | -517.61% | |
45 Neutral | ¥8.40B | -8.25 | -26.70% | ― | 60.80% | -8.89% | |
41 Neutral | ¥3.04B | -1.55 | ― | ― | -94.55% | 7.93% | |
41 Neutral | ¥121.06B | -33.74 | -10.16% | ― | -59.19% | -124.16% |
* Healthcare Sector Average
JP:4881
FunPep Company Limited
62.00
-53.00
-46.09%
JP:4587
Peptidream
925.10
-735.40
-44.29%
JP:4571
NanoCarrier Co., Ltd.
97.00
-35.00
-26.52%
JP:177A
Kohjin Bio Co.,Ltd.
1,019.00
-733.21
-41.84%
JP:2183
Linical Co., Ltd.
206.00
-108.29
-34.46%
JP:4570
Immuno-Biological Laboratories Co., Ltd.
945.00
432.20
84.28%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.